

# News Release

# Ashland reports preliminary financial results<sup>1</sup> for second quarter of fiscal year 2021

- Sales of \$598 million, down two percent from the prior-year quarter
- Net income of \$41 million, or \$0.66 per diluted share
- Income from continuing operations of \$43 million, or \$0.69 per diluted share
- Adjusted income from continuing operations excluding intangibles amortization expense of \$64 million, or \$1.05 per diluted share
- Adjusted EBITDA of \$134 million
- Cash flows provided by operating activities of \$64 million; free cash flows of \$40 million

WILMINGTON, Del., April 28, 2021 – Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary<sup>1</sup> financial results for the second quarter of fiscal year 2021, which ended March 31, 2021. The global specialty materials company serves customers in a wide range of consumer and industrial markets.

Ashland's financial results during the quarter reflected execution of the company's strategy, the benefit of continued cost reduction and improving industrial demand. Results were negatively impacted by the weather-related events in the U.S. Gulf Coast and changing consumer habits as the global pandemic has persisted. Sales were approximately \$598 million, down two percent compared to the prior-year period, reflecting the combined effect of these dynamics.

Net income was \$41 million compared to a net loss of \$582 million in the prior-year quarter which included the impact of a non-cash goodwill impairment charge. Income from continuing operations was \$43 million compared to a loss of \$575 million in the prior-year quarter, or \$0.69 per diluted share compared to a loss of \$9.48 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was \$64 million compared to \$69 million in the prior-year quarter, or \$1.05 per diluted share, down from \$1.12 in the prior-year quarter. Adjusted EBITDA was \$134 million, down from \$142 million in the prior-year quarter, driven primarily by weather-related impacts following the winter storms in the U.S. Gulf Coast and higher-than-expected environmental reserves.

Ashland's two Texas-based facilities were shut down during the quarter for a period following the winter storms in the U.S. Gulf Coast. Weather-related impacts during the quarter totaled approximately \$11 million, comprised primarily of lost cost absorption, repair costs and increased freight costs. Unrelated to the winter storms, the company also incurred higher-than-expected environmental reserves of approximately \$4 million.

Cash flows provided by operating activities totaled \$64 million compared to \$47 million in the prior-year quarter. Free cash flows totaled \$40 million compared to \$10 million in the prior-year quarter.

"Absent the weather-related impacts, all of Ashland's business units performed as expected during the quarter," said Guillermo Novo, chairman and chief executive officer, Ashland. "The industrial businesses continued to gain further momentum as demand in those end markets accelerated. The Life Sciences segment saw continued strength in demand in the pharma and nutraceutical end markets, while the Personal Care and Household segment continued to experience the same consumer-driven impacts that have persisted during the global pandemic."

"I am pleased with the progress our team has made executing our strategy, especially in the context of a difficult operating environment," continued Novo. "The persistence of the global pandemic-impacted consumer behavior and the winter storms in the U.S. Gulf Coast are realities we faced during the quarter. For the full fiscal year, we expect to recover a portion of the lost cost absorption as the impacted plants work to make up for some of the lost production during the quarter. Overall, our expectations for Ashland's full year results have not changed. I look forward to sharing additional thoughts on our plans and the progress we have made during our earnings call tomorrow morning."

# Reportable Segment Performance

To aid in the understanding of Ashland's ongoing business performance, the results of Ashland's reportable segments are described below on an adjusted basis. In addition, EBITDA and adjusted EBITDA are reconciled to operating income in Table 4. Free cash flow and adjusted operating income are reconciled in Table 6 and adjusted income from continuing operations, adjusted diluted earnings per share and adjusted diluted earnings per share excluding intangible amortization expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the "Use of Non-GAAP Measures" section that further describes these adjustments below.

# **Consumer Specialties**

Sales were \$322 million, down six percent from the prior-year quarter. Pharma sales were nearly flat with the strong prior-year period, while nutraceuticals sales reflected an improved demand environment. Sales in Personal Care and Household were down compared to the prior year due primarily to the exit of low-margin products and changing global consumer behavior for styling, grooming and oral-care during the global pandemic. Foreign currency favorably impacted sales by three percent.

Operating income was \$54 million, compared to a loss of \$300 million in the prior-year quarter which included the impact of the non-cash goodwill impairment charge. Adjusted EBITDA was \$88 million, down three percent from the prior-year quarter, reflecting the \$11 million weather-related impact of the U.S. Gulf Coast winter storms.

#### **Industrial Specialties**

Sales were \$246 million, up three percent from the prior-year quarter. Continued strong demand for architectural coatings and adhesives applications was partially offset by weak energy markets in the U.S. and lower construction additive sales following the labor strike at the Doel, Belgium facility. Foreign currency favorably impacted sales by three percent.

Operating income was \$38 million, compared to a loss of \$145 million in the prior-year quarter which included the impact of the non-cash goodwill impairment charge. Adjusted EBITDA was \$62 million, up 17% from the prior-year quarter, driven by favorable mix and SARD expenses.

#### Intermediates & Solvents

Sales were \$37 million, consistent with the prior-year quarter, as higher merchant sales offset lower internal sales following the winter storms in the U.S. Gulf Coast.

Operating income was \$3 million, up from an operating loss of \$2 million in the prior-year quarter. Adjusted EBITDA was \$7 million, up from \$5 million in the prior-year quarter.

# **Unallocated & Other**

Unallocated and Other expense was \$24 million, compared to \$21 million in the prior-year quarter. Adjusted Unallocated and Other expense was \$23 million, compared to an expense of \$7 million in the

prior-year quarter, primarily due to higher legacy environmental costs and favorable one-time income items recorded during the prior year.

# **Conference Call Webcast**

Ashland will host a live webcast of its first-quarter conference call with securities analysts at 10:00 a.m. ET on Thursday, April 29, 2021. The webcast will be accessible through Ashland's website at <a href="http://investor.ashland.com">http://investor.ashland.com</a> and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months on <a href="http://investor.ashland.com">http://investor.ashland.com</a>.

#### **Use of Non-GAAP Measures**

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides

investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

Adjusted diluted earnings per share, excluding intangibles amortization expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland's management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

#### **About Ashland**

Ashland Global Holdings Inc. (NYSE: ASH) is a premier specialty materials company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 4,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit <u>ashland.com</u> and <u>ashland.com/sustainability</u> to learn more.

#### **Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the U.S. Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance, financial condition, and expected effects of the COVID-19 pandemic on Ashland's business, as well as the economy and other future events or circumstances. These statements include but may not be limited to Ashland's expectations regarding its ability to drive sales and earnings growth and realize further cost reductions.

Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, public-health crises (including the current COVID-19 pandemic), cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); the effects of the COVID-19 pandemic on the geographies in which we operate, the end markets we serve and on our supply chain and customers, and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. The extent and duration of the COVID-19 pandemic on our business and operations is uncertain. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

Financial results are preliminary until Ashland's Form 10-Q is filed with the U.S. Securities and Exchange Commission.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

#### FOR FURTHER INFORMATION:

Investor Relations: Media Relations:

Seth A. Mrozek +1 (302) 594-5010 samrozek@ashland.com Carolmarie C. Brown +1 (302) 995-3158 <u>ccbrown@ashland.com</u>

Three months ended Six months ended March 31 March 31 2021 2020 2021 2020 \$ \$ 598 \$ 1,149 \$ 1.143 Sales 610 Cost of sales 407 413 781 793 197 368 **GROSS PROFIT** 191 350 Selling, general and administrative expense 103 190 84 202 Research and development expense 14 18 29 34 Intangibles amortization expense 22 43 21 42 Equity and other income 7 6 7 Goodwill impairment 530 530 **OPERATING INCOME (LOSS)** 71 112 (468)(451)Net interest and other expense 23 17 117 127 Net income (loss) on acquisitions and divestitures (5)9 3 **INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES** 43 104 (585)(575)Income tax expense (benefit) (10)(34)**INCOME (LOSS) FROM CONTINUING OPERATIONS** 43 (575)104 (541)Loss from discontinued operations (net of income taxes) (2)(9)(7)(7)**NET INCOME (LOSS)** 41 (582)97 (550)**DILUTED EARNINGS PER SHARE** (9.48)Income (loss) from continuing operations 0.69 1.69 (8.93)Income (loss) from discontinued operations (0.03)(0.13)(0.12)(0.15)Net income (loss) 0.66 (9.61)1.57 (9.08)AVERAGE DILUTED COMMON SHARES OUTSTANDING (a) 62 61 62 61 **SALES** 185 184 355 340 Life Sciences Personal Care and Household 137 159 262 296 **Consumer Specialties** 322 343 617 636 158 155 305 294 Specialty Additives Performance Adhesives 88 173 85 159 Industrial Specialties 246 240 478 453 Intermediates & Solvents 37 37 69 64 **Intersegment Sales** (10)(15)(10)(7)598 610 1.149 1.143 **OPERATING INCOME (LOSS)** 36 64 Life Sciences 35 58 Personal Care and Household 19 (336)33 (326)**Consumer Specialties** 54 (300)97 (268)Specialty Additives 19 21 (152)(161)Performance Adhesives 19 16 39 27 **Industrial Specialties** 38 60 (125)(145)Intermediates & Solvents 3 (2)5 (14)Unallocated and other (44)(24)(21)(50)71 (468)112 (451)

<sup>(</sup>a) As a result of the loss from continuing operations for the three and six months ending March 31, 2020, the effect of the share-based awards convertible to common shares would be anti-dilutive. In accordance with U.S. GAAP, these shares have been excluded from the diluted earnings per share calculation for the applicable periods.

		March 31 2021							
ASSETS									
Current assets									
Cash and cash equivalents	\$	373	\$	454					
Accounts receivable		447		471					
Inventories		512		529					
Other assets		86		87					
Held for sale		-		6					
Total current assets		1,418		1,547					
Noncurrent assets									
Property, plant and equipment									
Cost		3,307		3,265					
Accumulated depreciation		1,775		1,700					
Net property, plant and equipment		1,532		1,565					
Goodwill		1,760		1,758					
Intangibles		971		1,013					
Operating lease assets, net		132		137					
Restricted investments		302		301					
Asbestos insurance receivable		128		136					
Deferred income taxes		26		26					
Other assets		395		394					
Total noncurrent assets		5,246		5,330					
Total assets	<u>\$</u>	6,664	\$	6,877					
LIABILITIES AND EQUITY									
Current liabilities									
Short-term debt	\$	85	\$	280					
Current portion of long-term debt		3		-					
Trade and other payables		217		233					
Accrued expenses and other liabilities		241		277					
Current operating lease obligations		23		23					
Total current liabilities		569		813					
Noncurrent liabilities									
Long-term debt		1,571		1,573					
Asbestos litigation reserve		489		513					
Deferred income taxes		229		229					
Employee benefit obligations		152		157					
Operating lease obligations		119		124					
Other liabilities		421		432					
Total noncurrent liabilities		2,981		3,028					
Stockholders' equity		3,114		3,036					
Total liabilities and stockholders' equity	\$	6,664	\$	6,877					

CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES   FROM CONTINUING OPERATIONS			Three months ended March 31				Six months ended March 31					
Net income (loss)			2021		2020		2021		2020			
Netincome   Loss    Cincome   Loss   C	CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES	-										
Adjustments to reconcile income from continuing operations (see the section of												
Adjustments to reconcile income from continuing operations to cash flows from operating activities	,	\$		\$		\$		\$	, ,			
Cash flows from operating activities   124   122   122   126   126   124   122   122   122   123   123   124   124   125   1			2		7		7		9			
Depreciation and amortization												
Oniginal issue discount and debt issuance cost amortization         1         10         3         12           Deferred income taxes         (6)         (16)         (12)         (28)           Gain from sales of property and equipment         -         -         (3)         -           Stock based compensation expense         4         4         4         8         8           Excess tax benefit on stock based compensation         -         59         -         59           (Income) loss from restricted investments         4         -         -         150         9         59           (Income) loss from restricted investments         4         -         -         111         -         -         530         9         530         9         530         9         530         9         530         9         530         9         530         9         530         9         530         1         530         9         530         9         530         9         530         9         530         9         530         9         530         9         530         1         (11)         -         (11)         1         -         (11)         (3)         (5         66	·											
Deferred income taxes	·											
Gain from sales of property and equipment         :         (3)         :         1         2         1         2         1         2         1 <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·											
Distributions from equity affiliates			(6)		(16)		٠,		(28)			
Stock based compensation expense         4         4         8         8           Excess tax barelifit on stock based compensation         1					-				-			
Excess tax benefit on stock based compensation	· ·		=		-				-			
Loss on early retirement of debt	· · · · · · · · · · · · · · · · · · ·											
(Income) loss from restricted investments         4         29         (19)         1.5           (Income) loss on acquisitions and divestitures         4         -         (11)         -           Impairments         2.0         (2)         (2)         (4)         (3)           Change in operating assets and liabilities (a)         (28)         (54)         (31)         (163)           CASH FLOWS PROVIDED (USED) BY INVESTING SCRIVITIES         8         4         4         7         70         13           CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES         FROM CONTINUING OPERATIONS         6         4         7         10         1         1         1         1         -         5         5         6         6         7         1         1         -         1         1         -         1         1         -         1         1         -         -         1         1         -         -         1         1         -         -         1         1         -         -         1         -         -         1         1         -         -         1         1         -         -         -         1         1         -         -         -	·		1				1					
(Income) loss on acquisitions and divestitures         4         (1)         530         9         530           Pension contributions         (2)         (2)         (4)         (3)         9         530           Pension contributions         (48)         (54)         (51)         (16)         (16)         (17)         13           Total cash flows provided by operating activities from continuing operations         64         47         170         13           CASH FLOWS PROVIDED (USED) BY NWESTING ACTIVITIES         64         47         170         13           FROM CONTINUING OPERATIONS         7         (55)         (66)         67         14         1	·		-				- (40)					
Impairments	` ,				29		, ,		16			
Pension contributions	·		4				, ,					
Change in operating assets and liabilities (a)         (48)         (54)         (31)         (163)           Total cash flows provided by operating activities from continuing operations         64         47         170         13           CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES         FROM CONTINUING OPERATIONS         S         (65)         (66)           Additions to property, plant and equipment         24         37         (55)         (66)           Proceeds from sale or restructuring of operations         1         4         4         -           Net purchase of funds restricted for spedific transactions         1         (1)         (1)         (2)           Reimbursements from restricted investments         10         9         18         19           Proceeds from sale of securities         5         6         47         10           Purchases of securities         (5)         (6)         (47)         (10)           Total cash flows used by investing activities from continuing operations         (15)         (29)         (20)         (49)           Proceeds from sisuance of long-term debt         -         804         -         804           Repayment of long-term debt         -         (767)         -         (767)           Proceeds	·											
Total cash flows provided by operating activities from continuing operations   CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES			. ,									
Additions to property, plant and equipment   (24)   (37)   (55)   (66)     Proceeds from disposal of property, plant and equipment   (24)   (37)   (55)   (66)     Proceeds from sale or restructuring of operations   (1)   (1)   (1)   (2)     Reimbursements estricted for specific transactions   (1)   (1)   (2)     Reimbursements from restricted investments   (10)   (9)   (18)   (10)     Proceeds from sale or restructuring of operations   (10)   (9)   (18)   (10)     Reimbursements from restricted investments   (10)   (9)   (18)   (10)     Proceeds from sale of securities   (10)   (10)   (10)   (10)     Purchases of securities   (10)   (10)   (10)   (10)     Purchases of securities   (10)   (10)   (10)   (10)     Purchases of securities   (10)   (10							. ,		, ,			
PROM CONTINUING OPERATIONS			64		47		170		13			
Additions to property, plant and equipment         (24)         (37)         (55)         (66)           Proceeds from disposal of property, plant and equipment         -         -         14         -           Proceeds from sale or restructuring of operations         (1)         -         (11)         -           Net purchase of funds restricted for specific transactions         -         (11)         (11)         -           Net purchase of securities         10         9         18         19           Proceeds from sale of securities         5         6         47         100           Purchases of securities         (5)         (6)         (47)         (10)           Total cash flows used by investing activities from continuing operations         (15)         (29)         (20)         (49)           CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES         Total cash flows used by investing activities from continuing operations         -         804         Respayment of long-term debt         -         804         Respayment of long-term debt         -         804         Respayment of long-term debt         -         (767)         -         (767)         7675         (767)         7676         7676         7679         Proceeds from issuance ost sections from term term term term term term term ter												
Proceeds from disposal of property, plant and equipment         -         -         14         -           Proceeds from sale or restructuring of operations         -         -         14         -           Company-owned life insurance payments         (1)         -         (1)         -           Net purchase of funds restricted for specific transactions         -         (1)         (1)         (2)           Reimbursements from restricted investments         5         6         47         10           Proceeds from sale of securities         (5)         (6)         47         (10)           Total cash flows used by investing activities from continuing operations         (15)         (29)         (20)         (49)           CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES         From the continuing operations         -         (767)         -         804         -         804           Repayment of long-term debt         -         8         804         -         804           Repayment of long-term debt         -         (767)         -         (767)         -         (767)           Proceeds from (repayment of ) short-term debt         -         -         (11)         -         (19)         1           Proceeds from (long-term debt			(24)		(37)		(55)		(66)			
Proceeds from sale or restructuring of operations			(24)		(07)		٠,		(00)			
Company-owned life insurance payments			_		_				_			
Net purchase of funds restricted for specific transactions         -         (1)         (1)         (2)           Reimbursements from restricted investments         10         9         18         19           Proceeds from sale of securities         5         6         47         10           Purchases of securities         (5)         (6)         47         (10)           Total cash flows used by investing activities from continuing operations         (5)         (6)         47         (10)           Total cash flows used by investing activities from continuing operations         (5)         (6)         47         (10)           Total cash flows used by investing activities from continuing operations         (5)         (20)         (20)         (49)           CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES         Total cash flow in susuance of long-term debt         2         804         -         804           Repayment of long-term debt         (8)         292         (195)         306           Proceeds from insusance costs         (8)         292         (195)         30           Permium on long-term debt repayment         (8)         (2)         (11)         (11)         (11)         (11)         (11)         (11)         (20)         (11)         (20)	9 !		(1)		_				_			
Reimbursements from restricted investments   10			(1)		(1)				(2)			
Proceeds from sale of securities         5         6         47         10           Prurchases of securities         (5)         (6)         (47)         (10)           Total cash flows used by investing activities from continuing operations         (15)         (29)         (20)         (40)           CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES         The Comment of the Comment of Comm	·		10									
Purchases of securities												
Total cash flows used by investing activities from continuing operations   CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES   FROM CONTINUING OPERATIONS   Substituting the part of long-term debt   Substituting operation   Subs												
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS   S04   Proceeds from issuance of long-term debt   Proceeds from issuance of long-term debt payment   Proceeds from issuance costs   Proceeds from issuance payment   Proceeds fro		_		_		_		_				
Proceeds from issuance of long-term debt         -         (767)         -         (767)           Repayment of long-term debt         -         (767)         -         (767)           Proceeds from (repayment of) short-term debt         (8)         292         (195)         306           Premium on long-term debt repayment         -         (59)         -         (59)           Debt issuance costs         -         (11)         -         (11)           Cash dividends paid         (17)         (17)         (33)         333           Stock based compensation employee withholding taxes paid in cash         (2)         (1)         (5)         (6)           Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (233)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           CASH provided (used) by discontinued operations         27         (24)         (23)         (23)         23           Cash provided (used) by discontinued operations         21         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         -         4         1 <td>CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES</td> <td></td> <td>(13)</td> <td></td> <td>(29)</td> <td></td> <td>(20)</td> <td></td> <td>(49)</td>	CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES		(13)		(29)		(20)		(49)			
Repayment of long-term debt			_		804		_		804			
Proceeds from (repayment of) short-term debt         (8)         292         (195)         306           Premium on long-term debt repayment         -         (59)         -         (59)           Debt issuance costs         -         (11)         -         (111)           Cash dividends paid         (17)         (17)         (33)         (33)           Stock based compensation employee withholding taxes paid in cash         (2)         (1)         (5)         (6)           Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (233)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         22         259         (83)         198           Cash provided (used) by discontinued operations         21         (6)         (1)         (9)         1           Investing cash flows         (6)         (1)         (9)         1         1         -         4         1         1         -         4         1         1         -         4         1         1         -         4         1         1         -         -         4         1	<u>u</u>		_				_					
Premium on long-term debt repayment         -         (59)         -         (59)           Debt issuance costs         -         (11)         -         (11)           Cash dividends paid         (17)         (17)         (17)         (33)         (33)           Stock based compensation employee withholding taxes paid in cash         (2)         (11)         (5)         (6)           Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (233)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         21         (62)         7         (79)           Investing cash flows         31         38         196         (81)         121			(8)		, ,		(195)		, ,			
Debt issuance costs			-				-					
Cash dividends paid         (17)         (17)         (33)         (33)           Stock based compensation employee withholding taxes paid in cash         (2)         (1)         (5)         (6)           Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (23)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         21         (62)         7         (79)           Investing cash flows         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         38         196         (81)         121           CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$373         \$353         \$373         \$353           DEPRECIATION AND AMORTIZATION         3         15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties </td <td></td> <td></td> <td>_</td> <td></td> <td>. ,</td> <td></td> <td>_</td> <td></td> <td></td>			_		. ,		_					
Stock based compensation employee withholding taxes paid in cash         (2)         (1)         (5)         (6)           Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (233)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         21         (62)         7         (79)           Investing cash flows         21         (62)         7         (79)           Investing cash flows         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           Effect of Currency exchange rate changes on cash and cash equivalents         38         196         (81)         121           CASH AND CASH EQUIVALENTS - END OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$373         \$353         \$373         \$353           DEPRECIATION AND AMORTIZATION           Life Sciences         15         15         31         30           Personal Care and Household         19         19         38			(17)		. ,		(33)		, ,			
Total cash flows provided (used) by financing activities from continuing operations         (27)         241         (233)         234           CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         321         (62)         7         (79)           Operating cash flows         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         38         196         (81)         121           CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$ 373         \$ 353         \$ 373         \$ 353           DEPRECIATION AND AMORTIZATION         \$ 15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6	•		. ,		. ,							
CASH PROVIDED (USED) BY CONTINUING OPERATIONS         22         259         (83)         198           Cash provided (used) by discontinued operations         3         (62)         7         (79)           Operating cash flows         21         (62)         7         (79)           Investing cash flows         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         38         196         (81)         121           CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$373         \$353         \$373         \$353           DEPRECIATION AND AMORTIZATION         15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties												
Cash provided (used) by discontinued operations         Operating cash flows       21       (62)       7       (79)         Investing cash flows       (6)       (1)       (9)       1         Effect of currency exchange rate changes on cash and cash equivalents       1       -       4       1         INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS       38       196       (81)       121         CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD       335       157       454       232         CASH AND CASH EQUIVALENTS - END OF PERIOD       \$ 373       \$ 353       \$ 373       \$ 353         DEPRECIATION AND AMORTIZATION       Uife Sciences       15       15       31       30         Personal Care and Household       19       19       38       38         Consumer Specialties       34       34       34       69       68         Specialty Additives       21       20       42       40         Performance Adhesives       3       4       6       7         Industrial Specialties       24       24       48       47         Intermediates & Solvents       4       3       7       7         Unallocated and other       -       -												
Operating cash flows         21         (62)         7         (79)           Investing cash flows         (6)         (1)         (9)         1           Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         38         196         (81)         121           CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$ 373         \$ 353         \$ 373         \$ 353           DEPRECIATION AND AMORTIZATION         Using Sciences         15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -							(00)					
Investing cash flows   (6) (1) (9) 1			21		(62)		7		(79)			
Effect of currency exchange rate changes on cash and cash equivalents         1         -         4         1           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         38         196         (81)         121           CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$ 373         \$ 353         \$ 373         \$ 353           DEPRECIATION AND AMORTIZATION         Using the second of the control of the con	· · ·				, ,				, ,			
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   38   196   (81)   121												
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD         335         157         454         232           CASH AND CASH EQUIVALENTS - END OF PERIOD         \$ 373         \$ 353         \$ 373         \$ 353           DEPRECIATION AND AMORTIZATION           Life Sciences         15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -		-				_		_				
CASH AND CASH EQUIVALENTS - END OF PERIOD         \$ 373         \$ 353         \$ 373         \$ 353           DEPRECIATION AND AMORTIZATION           Life Sciences         15         15         31         30           Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -	· · · · · · · · · · · · · · · · · · ·	_		_		_		_				
DEPRECIATION AND AMORTIZATION         Life Sciences       15       15       31       30         Personal Care and Household       19       19       38       38         Consumer Specialties       34       34       69       68         Specialty Additives       21       20       42       40         Performance Adhesives       3       4       6       7         Industrial Specialties       24       24       48       47         Intermediates & Solvents       4       3       7       7         Unallocated and other       -       -       -       -       -		Ф		¢		Ф		•				
Life Sciences       15       15       31       30         Personal Care and Household       19       19       38       38         Consumer Specialties       34       34       69       68         Specialty Additives       21       20       42       40         Performance Adhesives       3       4       6       7         Industrial Specialties       24       24       48       47         Intermediates & Solvents       4       3       7       7         Unallocated and other       -       -       -       -       -	CASH AND CASH EQUIVALENTS - END OF FERIOD	Φ	3/3	Ψ	333	φ	313	φ	333			
Personal Care and Household         19         19         38         38           Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -	DEPRECIATION AND AMORTIZATION											
Consumer Specialties         34         34         69         68           Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -	Life Sciences		15		15		31		30			
Specialty Additives         21         20         42         40           Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -	Personal Care and Household		19		19		38		38			
Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -         -         -	Consumer Specialties	-	34		34		69		68			
Performance Adhesives         3         4         6         7           Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -         -         -	Specialty Additives		21		20		42		40			
Industrial Specialties         24         24         48         47           Intermediates & Solvents         4         3         7         7           Unallocated and other         -         -         -         -         -         -	Performance Adhesives		3		4		6		7			
Intermediates & Solvents         4         3         7         7           Unallocated and other         - <td>Industrial Specialties</td> <td></td> <td>24</td> <td></td> <td>24</td> <td></td> <td>48</td> <td></td> <td>47</td>	Industrial Specialties		24		24		48		47			
	Intermediates & Solvents		4		3		7		7			
\$ 62 \$ 61 \$ 124 \$ 122	Unallocated and other		-		-		-		-			
		\$	62	\$	61	\$	124	\$	122			

<sup>(</sup>a) Excludes changes resulting from operations acquired or sold.

		Three mor	nths en ch 31	ıded
Adjusted EBITDA - Ashland Global Holdings Inc.		2021		2020
Net income (loss)	\$	41	\$	(582)
Income tax expense (benefit)		-		(10)
Net interest and other expense		23		117
Depreciation and amortization		62		61
EBITDA		126		(414)
Loss from discontinued operations (net of taxes)		2		` 7 <sup>°</sup>
Net loss on acquisitions and divestitures key items (see Table 5)		5		-
Operating key items (see Table 5)		1		549
Adjusted EBITDA	\$	134	\$	142
Life Sciences Operating income		35	\$	36
Add:	Ψ	00	Ψ	00
Depreciation and amortization		15		15
Operating key items (see Table 5)		-		1
Adjusted EBITDA	\$	50	\$	52
- <b> </b>	<del>*</del>		<del>* -</del>	
Personal Care and Household				
Operating income (loss)	\$	19	\$	(336)
Add:				
Depreciation and amortization		19		19
Operating key items (see Table 5)		-		356
Adjusted EBITDA	<u>\$</u>	38	<u>\$</u>	39
Adjusted EBITDA - Consumer Specialties Total				
Operating income (loss)	\$	54	\$	(300)
Add:				
Depreciation and amortization		34		34
Operating key items (see Table 5)		-	•	357
Adjusted EBITDA	\$	88	<u>\$</u>	91

	-	nded		
	2021			2020
Specialty Additives			_	
Operating income (loss)	\$	19	\$	(161)
Add:  Depresiation and emertization		21		20
Depreciation and amortization Operating key items (see Table 5)		۷۱		174
Adjusted EBITDA	\$	40	\$	33
Adjusted EDIT DA	Ψ	<del></del>	Ψ	
Performance Adhesives				
Operating income	\$	19	\$	16
Add:				
Depreciation and amortization		3		4
Adjusted EBITDA	\$	22	\$	20
Adjusted EBITDA - Industrial Specialties Total			_	
Operating income (loss)	\$	38	\$	(145)
Add:		0.4		0.4
Depreciation and amortization Operating key items (see Table 5)		24		24 174
Adjusted EBITDA	\$	62	\$	53
Adjusted EDITEA	Ψ	02	Ψ	
Adjusted EBITDA - Intermediates and Solvents				
Operating income (loss)	\$	3	\$	(2)
Add:				
Depreciation and amortization		4		3
Operating key items (see Table 5)				4
Adjusted EBITDA	\$	7	\$	5

# Ashland Global Holdings Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE INCOME STATEMENT CAPTIONS

(In millions - preliminary and unaudited)

							1	Three Moi	nths End	ed Marc	h 31. 202	21					
		ife ences	Pers Ca ar Hous	are nd		sumer ialties		cialty	Perform Adhes	ance	Indus Specia	trial	Intermediate		Unallocated & Other	-	Total
OPERATING INCOME (LOSS)		<u> </u>	11000	onoid	Орос	iaitioo	71001		7101100	1100	Ороск		una conventa		<u> </u>		rotar
Operating key items:	_								_		_		_				
Restructuring, separation and other costs All other operating income (loss)	\$	- 35	\$	19	\$	54	\$	- 19	\$	- 19	\$	38	\$	- ( 3	\$ (1) (23)	\$	(1) 72
Operating income (loss)		35 35		19		54		19		19		38		3	(24)		71
NET INTEREST AND OTHER EXPENSE																	
Key items															7		7
All other net interest and other expense (income)														=	16 23		16 23
NET INCOME (LOSS) ON ACQUISITIONS AND DIVESTITURES																	
Key items															(5)		(5)
INCOME TAX EXPENSE (BENEFIT)															2		2
Tax effect of key items (a) Tax specific key items (b)															7		2 7
All other income tax expense (benefit)														-	(9)		<u>(9</u> )
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	35	\$	19	\$	54	\$	19	\$	19	\$	38	\$	3 5	\$ (52)	\$	43
								Three Mo	nths End	led Mare	ch 31, 20	20					
				sonal													
		ife ences	а	are nd sehold		sumer cialties		ecialty ditives		rmance esives		ustrial cialties	Intermedia and Solve		Unallocated & Other	i	Total
OPERATING INCOME (LOSS)		211003	11000	ocrioia	Орс	Ciditios	710	aitivos	71011	551465	ОРС	Ciartics	and borve	,1113	<u>u otner</u>		Total
Operating key items:																	
Restructuring, separation and other costs	\$	(1)	\$	(256)	\$	(1)	\$	(174)	\$	-	\$	- (174)	\$	-	\$ (1	4) \$	` '
Goodwill impairment Inventory adjustment		-		(356)		(356)		(174)		_		(174)		(4)		-	(530) (4)
All other operating income (loss)		37		20		57		13		16		29		2	(	<u>7</u> )	81
Operating income (loss)		36		(336)		(300)		(161)		16		(145)		(2)	(2	1)	(468)
NET INTEREST AND OTHER EXPENSE															•	•	20
Key items All other net interest and other expense															9:	8	99 18
INCOME TAX EXPENSE (BENEFIT)															11	7	117
Tax effect of key items (a)															(2	1)	(21)
Tax specific key items (b) All other income tax expense (benefit)															1	- 1	- 11
All other moonie tax expense (benefit)															(1)		(10)
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	36	\$	(336)	\$	(300)	\$	(161)	\$	16	\$	(145)	\$	(2)	\$ (12	<u>8</u> ) <u></u>	\$ (575)

<sup>(</sup>a) Represents the tax effect of the key items that are previously identified above.
(b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 7 for additional information.

(In millions - preliminary and unaudited)

	Th	ths ended ch 31						
Free cash flows (a)	2	021	2	020	2	021	2	020
Total cash flows provided by operating activities from continuing operations	\$	64	\$	47	\$	170	\$	13
Adjustments:								
Additions to property, plant and equipment		(24)		(37)		(55)		(66)
Free cash flows (a) (b)	\$	40	\$	10	\$	115	\$	(53)

Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if applicable).

Includes \$15 million and \$7 million of restructuring payments for the three months ended March 31, 2021 and 2020, and \$29 million and \$13 million for the six months ended March 31, 2021 and 2020, respectively.

	Th	Three months ended Six months e March 31 March 3							
Adjusted operating income	20	2021			2021		2	2020	
Operating income (loss) (as reported)	\$	\$ 71		(468)	\$	112	\$	(451)	
Key items, before tax:									
Restructuring, separation and other costs		1		15		13		22	
Goodwill impairment		-		530		-		530	
Inventory adjustments		-		4		-		4	
Capital project impairment		-		-		9		-	
Adjusted operating income (non-GAAP)	\$	72	\$	81	\$	134	\$	105	

# **RECONCILIATION OF CERTAIN NON-GAAP DATA**

(In millions except per share data - preliminary and unaudited)

	Thr	ee mor Marc		S	Six months ended March 31				
	20	21	2	020	20	021	2	2020	
Income (loss) from continuing operations (as reported)	\$	43	\$	(575)	\$	104	\$	(541)	
Key items, before tax:									
Restructuring, separation and other costs		1		15		13		22	
Unrealized loss (gain) on securities		7		32		(11)		23	
Goodwill impairment		-		530		-		530	
Inventory adjustments		-		4		-		4	
Accelerated amortization of debt issuance costs		-		8		-		8	
Loss on early retirement of debt		-		59		-		59	
Net loss (gain) on acquisitions and divestitures		5		-		(9)		-	
Capital project impairment				<u> </u>		9			
Key items, before tax		13		648		2		646	
Tax effect of key items (a)		(2)		(21)		2		(20)	
Key items, after tax		11		627		4		626	
Tax specific key items:									
Restructuring and separation activity		-		-		(13)		-	
Uncertain tax positions		(7)		-		(7)		-	
Other tax reform related activity								(25)	
Tax specific key items (b)		<u>(7</u> )				(20)		(25)	
Total key items		4		627		(16)		601	
Adjusted income from continuing operations (non-GAAP)	\$	47	\$	52	\$	88	\$	60	
Amortization expense adjustment (net of tax) (c)		17		17		34		34	
Adjusted income from continuing operations (non-GAAP) excluding intangibles	-								
amortization expense	\$	64	\$	69	\$	122	\$	94	

<sup>(</sup>a) Represents the tax effect of the key items that are previously identified above.

<sup>(</sup>b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

<sup>-</sup> Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

<sup>-</sup> Uncertain tax positions: Includes the impact from the settlement of uncertain tax positions with various tax authorities.

<sup>-</sup> Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.

<sup>(</sup>c) Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended March 31, 2021 and 2020 and 21% and 20% for the six months ended March 31, 2021 and 2020, respectively.

# RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions except per share data - preliminary and unaudited)

	TI	nree mon Marc			Six months end March 31				
		2021		2020	2021		2	2020	
Diluted EPS from continuing operations (as reported)	\$	0.69	\$	(9.48)	\$	1.69	\$	(8.93)	
Key items, before tax:									
Restructuring, separation and other costs		0.02		0.23		0.21		0.35	
Unrealized loss (gain) on securities		0.11		0.53		(0.18)		0.38	
Goodwill impairment		-		8.75		-		8.75	
Inventory adjustments		-		0.06		-		0.06	
Accelerated amortization of debt issuance costs		-		0.13		-		0.13	
Loss on early retirement of debt		-		0.97		-		0.97	
Net loss (gain) on acquisitions and divestitures		0.08		-		(0.16)		-	
Capital project impairment						0.16			
Key items, before tax		0.21		10.67		0.03		10.64	
Tax effect of key items (a)		(0.03)		(0.35)		0.03		(0.33)	
Key items, after tax		0.18		10.32		0.06		10.31	
Tax specific key items:									
Restructuring and separation activity		-		-		(0.22)		-	
Uncertain tax positions		(0.10)		-		(0.10)		-	
Other tax reform related activity								(0.41)	
Tax specific key items (b)		(0.10)				(0.32)		(0.41)	
Total key items		0.08		10.32		(0.26)		9.90	
Adjusted diluted EPS from continuing operations (non-GAAP)	\$	0.77	\$	0.84	\$	1.43	\$	0.97	
Amortization expense adjustment (net of tax) (c)		0.28		0.28		0.55		0.56	
Adjusted diluted EPS from continuing operations (non-GAAP) excluding intangibles	•		•		•		•		
amortization expense	\$	1.05	\$	1.12	\$	1.98	\$	1.53	

<sup>(</sup>a) Represents the tax effect of the key items that are previously identified above.

<sup>(</sup>b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

<sup>-</sup> Restructuring and separation activity. Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

<sup>-</sup> Uncertain tax positions: Includes the impact from settlement of uncertain tax positions with various tax authorities.

<sup>-</sup> Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.

<sup>(</sup>c) Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended March 31, 2021 and 2020 and 21% and 20% for the six months ended March 31, 2021 and 2020, respectively.